Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
48
49
Next >
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
July 10, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
Is Johnson & Johnson Stock a Buy Now?
July 09, 2023
Some businesses never go out of style.
Via
The Motley Fool
$1 Billion Deal For Moderna To Expand Product Pipeline in China
July 06, 2023
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher
Via
MarketBeat
Topics
ETFs
Economy
Exposures
COVID-19
Economy
The 3 Best Biotech Stocks to Buy In July
July 05, 2023
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up.
Via
InvestorPlace
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
July 05, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
This Is What Whales Are Betting On Gilead Sciences
June 30, 2023
Via
Benzinga
Looking Into Gilead Sciences's Recent Short Interest
June 29, 2023
Via
Benzinga
Gilead Sciences' Debt Overview
June 29, 2023
Via
Benzinga
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
June 30, 2023
Via
AB Newswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 30, 2023
Via
Benzinga
Amgen Inc. Dividend Stock Analysis
June 30, 2023
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years.
Via
Talk Markets
Ominous Death Cross Forms On Gilead Sciences's Chart
June 28, 2023
Via
Benzinga
Primary Sclerosing Cholangitis Market expected to rise | Companies – Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics
June 27, 2023
Via
AB Newswire
Expert Ratings for Gilead Sciences
June 23, 2023
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
June 22, 2023
Via
Benzinga
2 Low-Priced Stocks That Could Make You Richer
June 26, 2023
These two low-priced healthcare stocks could skyrocket within the next 12 months.
Via
The Motley Fool
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
June 23, 2023
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Via
News Direct
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
June 23, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for
Via
Benzinga
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
June 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Alleged Industrial Espionage Makes an Interesting Story
June 21, 2023
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
June 21, 2023
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.
Via
The Motley Fool
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
June 20, 2023
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.
Via
Investor's Business Daily
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
June 20, 2023
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for
Via
Benzinga
How to Retire Rich: Biotech Stocks Edition
June 18, 2023
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.
Via
InvestorPlace
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
June 16, 2023
Via
AB Newswire
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
June 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2022 R&D Spending and Intensity Benchmarks
June 12, 2023
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.